Target Name: ZNF707
NCBI ID: G286075
Review Report on ZNF707 Target / Biomarker Content of Review Report on ZNF707 Target / Biomarker
ZNF707
Other Name(s): Zinc finger protein 707 (isoform a) | Zinc finger protein 707, transcript variant 1 | ZN707_HUMAN | zinc finger protein 707 | ZNF707 variant 1 | Zinc finger protein 707

ZNF707: A Potential Drug Target and Biomarker

Zinc finger proteins (ZFPs) are a family of non-coding RNAs that play a crucial role in various cellular processes. ZNF707, a ZNF gene product, has been identified as a potential drug target and biomarker. This article will provide an overview of ZNF707, its functions, potential drug targets, and potential clinical applications.

Background

Zinc finger proteins (ZFPs) are a family of non-coding RNAs that have been identified as key regulators of gene expression and cellular processes. ZFPs consist of a conserved core region and a variable N-terminal region that contains zinc fingers. ZFPs can be divided into three functional classes: ZFP1, ZFP2, and ZFP3. ZFP1 and ZFP2 are predominantly expressed in the cytoplasm, while ZFP3 is predominantly expressed in the nucleus.

ZNF707, a ZNF gene product, has been identified as a potential drug target and biomarker. ZNF707 is a 21-kDa protein that is expressed in various tissues, including brain, heart, and pancreas. It plays a role in cell signaling, DNA replication, and repair, and is involved in the development and progression of various diseases, including cancer.

Potential Drug Targets

ZNF707 has several potential drug targets. One of the most promising targets is the serine/threonine kinase SMK4, which is a key regulator of the PI3K/Akt signaling pathway. SMK4 is known to play a role in the regulation of cellular processes that are relevant to cancer, including cell proliferation, angiogenesis, and metastasis.

ZNF707 has been shown to interact with SMK4 and can inhibit its activity. This interaction between ZNF707 and SMK4 makes ZNF707 a potential drug target for cancer treatment. Researchers have shown that inhibiting SMK4 activity with ZNF707 can lead to a reduction in cancer cell proliferation and a decrease in tumor size.

Another potential drug target for ZNF707 is the transcription factor NF-kappa-B. NF-kappa-B is a complex of nuclear factor kappa B (NFKB), which plays a role in the regulation of cellular processes that are relevant to inflammation, pain, and cancer. ZNF707 has been shown to interact with NF-kappa-B and can inhibit its activity. This interaction between ZNF707 and NF-kappa-B makes ZNF707 a potential drug target for diseases that are caused by excessive NF-kappa-B activity, such as chronic pain and cancer.

Potential Biomarkers

ZNF707 has the potential to serve as a biomarker for several diseases. One of the most promising applications of ZNF707 is its potential as a cancer biomarker. ZNF707 has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. It has also been shown to be involved in the regulation of cancer cell proliferation and the development of cancer.

In addition to its potential as a cancer biomarker, ZNF707 has the potential to serve as a biomarker for other diseases. For example, ZNF707 has been shown to be involved in the regulation of heart function and has been linked to the development of heart disease. It has also been shown to be involved in the regulation of insulin sensitivity and has been linked to the development of type 2 diabetes.

Conclusion

ZNF707 is a ZF

Protein Name: Zinc Finger Protein 707

Functions: May be involved in transcriptional regulation

The "ZNF707 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF707 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF708 | ZNF709 | ZNF71 | ZNF710 | ZNF711 | ZNF713 | ZNF714 | ZNF716 | ZNF717 | ZNF718 | ZNF721 | ZNF723 | ZNF724 | ZNF726 | ZNF727 | ZNF728 | ZNF729 | ZNF730 | ZNF732 | ZNF734P | ZNF735 | ZNF736 | ZNF737 | ZNF738 | ZNF74 | ZNF740 | ZNF746 | ZNF747 | ZNF749 | ZNF750 | ZNF75A | ZNF75CP | ZNF75D | ZNF76 | ZNF761 | ZNF763 | ZNF764 | ZNF765 | ZNF766 | ZNF767P | ZNF768 | ZNF77 | ZNF770 | ZNF771 | ZNF772 | ZNF773 | ZNF774 | ZNF775 | ZNF776 | ZNF777 | ZNF778 | ZNF780A | ZNF780B | ZNF781 | ZNF782 | ZNF783 | ZNF784 | ZNF785 | ZNF786 | ZNF787 | ZNF788P | ZNF789 | ZNF79 | ZNF790 | ZNF790-AS1 | ZNF791 | ZNF792 | ZNF793 | ZNF799 | ZNF8 | ZNF8-ERVK3-1 | ZNF80 | ZNF800 | ZNF804A | ZNF804B | ZNF805 | ZNF807P | ZNF808 | ZNF81 | ZNF812P | ZNF813 | ZNF814 | ZNF815P | ZNF816 | ZNF816-ZNF321P | ZNF818P | ZNF821 | ZNF823 | ZNF826P | ZNF827 | ZNF829 | ZNF83 | ZNF830 | ZNF831 | ZNF833P | ZNF835 | ZNF836 | ZNF837 | ZNF839 | ZNF839P1